NicVAX™.: Aid to smoking cessation, nicotine vaccine.
NicVAX™.: Aid to smoking cessation, nicotine vaccine.
复制标题
DOI：
10.1358/dof.2006.031.03.975527
复制
发表时间：
2006-03-01
影响因子：
0.2
通讯作者：
Boyd, B.
中科院分区：
文献类型：
--
作者：
Boyd, B.
根据世界卫生组织（世卫组织）的数据，全世界吸烟者的人数约为13亿，并且烟草使用被认为每年在地球仪周围造成近500万人死亡。每年有很大比例的吸烟者试图戒烟，但只有不到5%的人能够保持戒烟。吸烟的成瘾作用部分是由于烟草烟雾中含有尼古丁。当尼古丁进入大脑时，它会刺激多巴胺和其他与愉悦效果相关的神经递质的释放。NicVAX（TM）尼古丁结合疫苗在实验动物和人体中激发出高滴度的尼古丁特异性抗体，从而阻断尼古丁向大脑的分布。基于NicVAX（TM）的潜在戒烟策略包括直接接种疫苗和尼古丁特异性抗体被动免疫。NicVAX（TM）已被证明在高达400 μ g的剂量下是安全的和良好耐受的。
According to the World Health Organization (WHO), the number of smokers worldwide is about 1.3 billion, and tobacco use is considered to be involved in nearly 5 million deaths each year around the globe. A large proportion of smokers try to quit each year, but fewer than 5% are able to maintain abstinence. The addictive effects of smoking are due, in part, to the nicotine contained in tobacco smoke. When nicotine enters the brain, it stimulates the release of dopamine and other neurotransmitters associated with pleasurable effects. The NicVAX (TM) nicotine conjugate vaccine elicits high titers of nicotine-specific antibodies in experimental animals and humans, which blocks nicotine distribution to the brain. Potential strategies to aid in smoking cessation based on NicVAX (TM) include direct vaccination and passive immunization with nicotine-specific antibodies. NicVAX (TM) has been shown to be safe and well tolerated at doses of up to 400 mu g.